Trump Signs Psychedelic Therapy Executive Order — Silo Pharma's PTSD Pipeline in the Spotlight

President Donald Trump has signed an executive order directing multiple federal agencies to accelerate research into psychedelic-based therapeutics and expand patient access, drawing fresh attention to pharmaceutical companies with relevant pipelines.

On the 18th (local time), President Trump signed the executive order mandating that federal agencies streamline the regulatory environment and fast-track research into psychedelic therapies. The move is expected to bring significant federal backing to the development of psychedelic-based treatments targeting mental health conditions including PTSD, depression, and anxiety disorders.

Silo Pharma's SPC-15: A Direct Beneficiary of the Shifting Regulatory Landscape

SILO, a Nasdaq-listed clinical-stage biopharmaceutical company, issued a statement on the 20th affirming that "Trump's executive order strengthens the strategic positioning of the SPC-15 program."

SPC-15 is an intranasal PTSD prophylactic designed as a serotonin 4 (5-HT4) receptor agonist. The candidate employs a nose-to-brain direct delivery mechanism, targeting both rapid therapeutic onset and improved patient compliance. It is built on intellectual property licensed from Columbia University and is being advanced through the FDA's 505(b)(2) regulatory pathway for expedited development.

Eric Weisblum, CEO of SILO, stated, "The national conversation around psychedelic therapeutics is moving in the direction the scientific community has signaled for years. We are confident that SPC-15 and our broader CNS pipeline will benefit from an increasingly favorable regulatory and clinical environment."

SPC-15 Development Milestones

SPC-15 is currently in preparation for IND (Investigational New Drug) discussions with the FDA, while a partnership to optimize the intranasal delivery device is also underway. The company previously entered into a partnership with clinical development services firm Allucent in November of last year, and received European patent approval in early April.

Beyond SPC-15, SILO's pipeline includes SP-26 for fibromyalgia and chronic pain, as well as a preclinical Alzheimer's program. In addition to its biopharmaceutical operations, the company is pursuing a dual strategy that incorporates a cryptocurrency treasury approach, including Bitcoin acquisitions and investments in Solana-based tokenized assets.

Federal Policy Shift Serves as a Sector Catalyst for Psychedelic Therapeutics

The mental health therapeutics market is substantial, with PTSD alone affecting millions of patients annually. The executive order is widely viewed as a potential policy inflection point for the broader class of psychedelic-derived therapeutics, which have long faced development constraints under the existing DEA regulatory framework.

📊 Related Stocks & ETFs

🧪 Psychedelic & CNS Biotech

· Silo Pharma (NASDAQ: SILO) — Direct beneficiary via SPC-15 PTSD program
· Compass Pathways (NASDAQ: CMPS) — Psilocybin-based depression therapy
· atai Life Sciences (NASDAQ: ATAI)
· Mind Medicine (NASDAQ: MNMD)
· Numinus Wellness (TSX: NUMI)
· MAPS Public Benefit Corp — Private

💊 Large-Cap Mental Health & CNS

· Jazz Pharmaceuticals (NASDAQ: JAZZ)
· Innoviva (NASDAQ: INVA)
· AbbVie (NYSE: ABBV)
· Eli Lilly (NYSE: LLY)

📈 ETFs

· Horizons Psychedelic Stock Index ETF (NEO: PSYK) — Canadian-listed
· AdvisorShares Psychedelics ETF (NYSE: PSIL)
· VanEck Biotech Holdings (NASDAQ: BBH) — Broad biotech exposure